Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:12 AM
Ignite Modification Date:
2025-12-25 @ 4:12 AM
NCT ID:
NCT05940220
Eligibility Criteria:
Inclusion criteria
1. Earn at least 8 points from EVEREST score (see Table 1.)
2. Adult patients (≥ 18 years)
3. A major clinical sign of volume overload including edema, ascites confirmed by abdominal ultrasound, or pleural effusion confirmed by chest x-ray or chest ultrasound without using iv furosemide.
4. Maintenance treatment with oral furosemide as a loop diuretic ≥20 mg for at least one month
5. Using SGLT2i drugs including canagliflozin, dapagliflozin, and empagliflozin for at least one month
Exclusion criteria
1. Systolic blood pressure less than 90 mmHg or mean arterial pressure less than 65 mmHg
2. Estimated glomerular filtration rate (eGFR) \<20 ml/min/1.73 m2
3. Using any diuretic agent except mineralocorticoid receptor antagonists including spironolactone and eplerenone
4. Simultaneous diagnosis of acute coronary syndrome, which is characterized by typical chest pain in addition to an increase in troponin level above the 99th percentile or electrocardiographic changes indicating ischemia or hospitalization as unstable angina.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05940220
Study Brief:
Protocol Section:
NCT05940220